Brain metastases trial tests skipping radiation when drugs work

NCT ID NCT06974370

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether people with brain metastases from solid tumors can avoid radiation therapy if their brain tumors shrink or stay stable with systemic treatments like immunotherapy, targeted therapy, or chemotherapy. About 45 participants will be monitored with regular brain scans, and radiation is only used if tumors progress. The goal is to see if this approach is feasible and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
systemic therapy (immunotherapy, targeted therapy, or chemotherapy)
What this could lead to
If successful, this could show that many patients with brain metastases can avoid radiation and its side effects, relying on systemic therapy alone for control.
What could go wrong
This is a small pilot study (45 people) and early results may not apply to all patients. Some participants may still need radiation if their brain tumors grow despite systemic therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Vermont Medical Center

    RECRUITING

    Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.